Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia

<b>Background:</b> Despite the progress achieved regarding survival rates in childhood acute lymphoblastic leukemia (ALL), relapsed or refractory disease still poses a therapeutic challenge. Inotuzumab ozogamicin is a CD22-directed monoclonal antibody conjugated to calicheamicin, which h...

Full description

Bibliographic Details

Published in:	Hematology Reports
Main Authors:	Athanasios Tragiannidis, Vassiliki Antari, Eleni Tsotridou, Theodoros Sidiropoulos, Aikaterini Kaisari, Maria Palabougiouki, Timoleon-Achilleas Vyzantiadis, Emmanuel Hatzipantelis, Assimina Galli-Tsinopoulou, Evgenios Goussetis
Format:	Article
Language:	English
Published:	MDPI AG 2024-09-01
Subjects:	acute lymphoblastic leukemia inotuzumab ozogamicin childhood
Online Access:	https://www.mdpi.com/2038-8330/16/4/56